JP4211966B2 - 免疫関連疾患を治療するための組成物及び方法 - Google Patents

免疫関連疾患を治療するための組成物及び方法 Download PDF

Info

Publication number
JP4211966B2
JP4211966B2 JP2001542530A JP2001542530A JP4211966B2 JP 4211966 B2 JP4211966 B2 JP 4211966B2 JP 2001542530 A JP2001542530 A JP 2001542530A JP 2001542530 A JP2001542530 A JP 2001542530A JP 4211966 B2 JP4211966 B2 JP 4211966B2
Authority
JP
Japan
Prior art keywords
polypeptide
acid sequence
amino acid
nucleic acid
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001542530A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530082A6 (ja
JP2003530082A (ja
Inventor
シャーマン フォン，
ゴッダード，オードリー
ゴドフスキー，ポール，ジェー．
グリマルディ，クリストファー，ジェー．
ガーニー，オースティン，エル．
ヒラン，ケネス，ジェー．
タマス，ダニエル
ワタナベ，コリン，ケー．
ウッド，ウィリアム，アイ．
ツァン，ツェミン．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/en
Priority claimed from PCT/US2000/004342 external-priority patent/WO2000078961A1/en
Priority claimed from PCT/US2000/014941 external-priority patent/WO2000073348A2/en
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2003530082A publication Critical patent/JP2003530082A/ja
Publication of JP2003530082A6 publication Critical patent/JP2003530082A6/ja
Application granted granted Critical
Publication of JP4211966B2 publication Critical patent/JP4211966B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001542530A 1999-11-30 2000-11-10 免疫関連疾患を治療するための組成物及び方法 Expired - Lifetime JP4211966B2 (ja)

Applications Claiming Priority (26)

Application Number Priority Date Filing Date Title
PCT/US1999/028313 WO2000032221A2 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization
US99/28313 1999-11-30
USPCT/US99/28313 1999-11-30
US17026299P 1999-12-09 1999-12-09
US60/170,262 1999-12-09
US17205999P 1999-12-23 1999-12-23
US60/172,059 1999-12-23
US17548100P 2000-01-11 2000-01-11
US60/175,481 2000-01-11
US17711800P 2000-01-20 2000-01-20
US60/177,118 2000-01-20
US00/04342 2000-02-18
USPCT/US00/04342 2000-02-18
PCT/US2000/004342 WO2000078961A1 (en) 1999-06-23 2000-02-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US18720200P 2000-03-03 2000-03-03
US60/187,202 2000-03-03
PCT/US2000/014941 WO2000073348A2 (en) 1999-06-02 2000-05-30 Methods and compositions for inhibiting neoplastic cell growth
USPCT/US00/14941 2000-05-30
US00/14941 2000-05-30
US20983200P 2000-06-05 2000-06-05
US60/209,832 2000-06-05
US00/23328 2000-08-24
USPCT/US00/23328 2000-08-24
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US60/000,000 2000-09-15
PCT/US2000/030873 WO2001040465A2 (en) 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2005235351A Division JP4242371B2 (ja) 1999-11-30 2005-08-15 免疫関連疾患を治療するための組成物及び方法
JP2008107191A Division JP2008301810A (ja) 1999-11-30 2008-04-16 免疫関連疾患を治療するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2003530082A JP2003530082A (ja) 2003-10-14
JP2003530082A6 JP2003530082A6 (ja) 2004-07-08
JP4211966B2 true JP4211966B2 (ja) 2009-01-21

Family

ID=27558595

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2001542530A Expired - Lifetime JP4211966B2 (ja) 1999-11-30 2000-11-10 免疫関連疾患を治療するための組成物及び方法
JP2005235351A Expired - Fee Related JP4242371B2 (ja) 1999-11-30 2005-08-15 免疫関連疾患を治療するための組成物及び方法
JP2006013034A Expired - Lifetime JP4226605B2 (ja) 1999-11-30 2006-01-20 免疫関連疾患を治療するための組成物及び方法
JP2008107191A Pending JP2008301810A (ja) 1999-11-30 2008-04-16 免疫関連疾患を治療するための組成物及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2005235351A Expired - Fee Related JP4242371B2 (ja) 1999-11-30 2005-08-15 免疫関連疾患を治療するための組成物及び方法
JP2006013034A Expired - Lifetime JP4226605B2 (ja) 1999-11-30 2006-01-20 免疫関連疾患を治療するための組成物及び方法
JP2008107191A Pending JP2008301810A (ja) 1999-11-30 2008-04-16 免疫関連疾患を治療するための組成物及び方法

Country Status (5)

Country Link
EP (1) EP1234036A2 (de)
JP (4) JP4211966B2 (de)
AU (1) AU3434601A (de)
CA (1) CA2390786A1 (de)
WO (1) WO2001040465A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503730B1 (en) 1997-06-19 2003-01-07 Schering Corporation Nucleic acids encoding a cysteine rich protein
US7307153B2 (en) * 1999-12-23 2007-12-11 Genentech, Inc. Antibodies that bind PRO9912
EP2290081A3 (de) * 1999-12-23 2012-08-01 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
US20030153015A1 (en) 2000-01-20 2003-08-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2005513084A (ja) * 2001-12-19 2005-05-12 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物及び方法
CA2518101A1 (en) * 2003-03-03 2005-06-09 Genentech, Inc. Compositions and methods for the treatment of systemic lupus erythematosis
JP2007518404A (ja) * 2003-12-16 2007-07-12 ジェネンテック・インコーポレーテッド 新規な遺伝子破壊、これに関する組成物と方法
SG190626A1 (en) 2008-05-05 2013-06-28 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2010128407A2 (en) 2009-05-05 2010-11-11 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US5874230A (en) * 1996-07-10 1999-02-23 Tularik, Inc. Assays using TRAF2-associated protein kinase polypeptides
AU4268097A (en) * 1996-09-12 1998-04-02 Human Genome Sciences, Inc. Chemokine alpha-4
JP2001506492A (ja) * 1996-12-05 2001-05-22 ヒューマン ゲノム サイエンシズ インク． ヒトケモカインβ−１３
AU6891098A (en) * 1997-04-10 1998-10-30 Genetics Institute Inc. Secreted expressed sequence tags (sests)
AU7962398A (en) * 1997-06-19 1999-01-04 Schering Corporation Mammalian genes; related reagents
WO1999038959A1 (en) * 1998-01-30 1999-08-05 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
IL139219A0 (en) * 1998-04-24 2001-11-25 Genentech Inc Fizz proteins

Also Published As

Publication number Publication date
JP2006068007A (ja) 2006-03-16
JP4226605B2 (ja) 2009-02-18
WO2001040465A3 (en) 2002-03-21
JP4242371B2 (ja) 2009-03-25
EP1234036A2 (de) 2002-08-28
CA2390786A1 (en) 2001-06-07
AU3434601A (en) 2001-06-12
JP2008301810A (ja) 2008-12-18
JP2006197937A (ja) 2006-08-03
WO2001040465A2 (en) 2001-06-07
JP2003530082A (ja) 2003-10-14

Similar Documents

Publication Publication Date Title
JP5401001B2 (ja) 免疫関連疾患の治療のための新規組成物と方法
US7153950B2 (en) Nucleic acids encoding an immune related polypeptide
JP2010220614A (ja) 免疫関連疾患の治療のための組成物と方法
JP2012254093A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2006515747A (ja) 免疫関連疾患の治療のための組成物と方法
JP2006516094A (ja) ナチュラルキラー細胞関連疾患の治療のための組成物と方法
JP2010088434A (ja) 免疫関連疾患の治療のための新規組成物と方法
US7282570B2 (en) Compositions and methods for the treatment of immune related diseases
JP2013051961A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2008301810A (ja) 免疫関連疾患を治療するための組成物及び方法
JP2010046065A (ja) インターロイキン−８と相同なポリペプチドとその治療用途
US7576182B1 (en) Compositions and methods for the treatment of immune related diseases
JP2005519590A (ja) 免疫関連疾患の治療のための組成物及び方法
JP2003530082A6 (ja) 免疫関連疾患を治療するための組成物及び方法
US7601514B2 (en) Nucleic acid encoding PRO10268 polypeptides
JP3988821B2 (ja) 免疫関連疾患を治療するための組成物及び方法
JP2006515748A (ja) リウマチ様関節炎の治療のための組成物と方法
US7381809B2 (en) Compositions and methods for the treatment of immune related diseases
US7365157B2 (en) PRO9912 polypeptides
US7344880B2 (en) Nucleic acid encoding PRO9912 polypeptides
EP1878795A2 (de) Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050511

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20050518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080526

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080626

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080728

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080821

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080930

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081023

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111107

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4211966

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111107

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121107

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121107

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131107

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term